Leukemia, Myeloid, Acute research hub
7 indexed studies · 3 currently recruiting
- active not recruitingPHASE1
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
This study is testing a new drug, JNJ-89853413, for people in the UK with certain types of blood cancer (relapsed or refractory AML or MDS) that haven't responded well to previous treatments. It aims to find a safe dose and see how well it works.
Canada · Spain · United Kingdom - active not recruitingPHASE1, PHASE2
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukaemia (AML) in adults. It's for people who can't have standard, strong chemotherapy. We're testing two combinations of new medicines with an existing drug (azacitidine) to see how safe and effective they are.
United States · Australia · Belgium - active not recruitingPHASE1
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
This study is testing a new drug called Bleximenib alongside standard treatments for acute myeloid leukaemia (AML). It aims to find the safest and most effective dose of Bleximenib when given with other AML medicines, and to understand its side effects.
United States · Australia · Canada - enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
Belgium · France · Georgia - active not recruitingPHASE3
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
This study looks at a new drug (AG-120) combined with a standard treatment (azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukaemia (AML) that has a particular gene change (IDH1 mutation). It compares this combination to azacitidine alone to see if it works better.
United States · Australia · Austria - recruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
United States · Australia · Austria - recruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
United States · Belgium · Canada